Minocycline repurposing in critical illness: Focus on stroke

T. Vivian Liao, Christy C. Forehand, David C Hess, Susan C. Fagan

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Stroke is a devastating disease associated with high morbidity and mortality. Despite the approved indication of systemic thrombolytic therapy in the United States for the acute management of ischemic stroke, its use is limited given a strict eligibility criteria and a risk for hemorrhagic transformation as a feared adverse effect. Many agents have been studied without success for neuroprotection in patients with stroke to reduce vascular injury and improve long-term functional outcomes. Minocycline is a tetracycline antibiotic that shows promise for its neuroprotective effects in multiple animal models and three human trials. It affects multiple pathways to reduce apoptosis, neuroinflammation, infarct size, and vascular injury. The aim of this review is to discuss current evidence for minocycline from pre-clinical and early clinical trials and its potential role in neuroprotection in patients with acute ischemic stroke.

Original languageEnglish (US)
Pages (from-to)2283-2290
Number of pages8
JournalCurrent Topics in Medicinal Chemistry
Volume13
Issue number18
DOIs
StatePublished - Nov 25 2013

Fingerprint

Minocycline
Critical Illness
Stroke
Vascular System Injuries
Thrombolytic Therapy
Neuroprotective Agents
Tetracycline
Animal Models
Clinical Trials
Apoptosis
Anti-Bacterial Agents
Morbidity
Mortality
Neuroprotection

Keywords

  • Critical illness
  • Ischemia
  • Minocycline
  • Neuroprotection
  • Stroke
  • Tetracycline

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Minocycline repurposing in critical illness : Focus on stroke. / Liao, T. Vivian; Forehand, Christy C.; Hess, David C; Fagan, Susan C.

In: Current Topics in Medicinal Chemistry, Vol. 13, No. 18, 25.11.2013, p. 2283-2290.

Research output: Contribution to journalArticle

Liao, T. Vivian ; Forehand, Christy C. ; Hess, David C ; Fagan, Susan C. / Minocycline repurposing in critical illness : Focus on stroke. In: Current Topics in Medicinal Chemistry. 2013 ; Vol. 13, No. 18. pp. 2283-2290.
@article{c106b87667284534b857c9ed780c5f42,
title = "Minocycline repurposing in critical illness: Focus on stroke",
abstract = "Stroke is a devastating disease associated with high morbidity and mortality. Despite the approved indication of systemic thrombolytic therapy in the United States for the acute management of ischemic stroke, its use is limited given a strict eligibility criteria and a risk for hemorrhagic transformation as a feared adverse effect. Many agents have been studied without success for neuroprotection in patients with stroke to reduce vascular injury and improve long-term functional outcomes. Minocycline is a tetracycline antibiotic that shows promise for its neuroprotective effects in multiple animal models and three human trials. It affects multiple pathways to reduce apoptosis, neuroinflammation, infarct size, and vascular injury. The aim of this review is to discuss current evidence for minocycline from pre-clinical and early clinical trials and its potential role in neuroprotection in patients with acute ischemic stroke.",
keywords = "Critical illness, Ischemia, Minocycline, Neuroprotection, Stroke, Tetracycline",
author = "Liao, {T. Vivian} and Forehand, {Christy C.} and Hess, {David C} and Fagan, {Susan C.}",
year = "2013",
month = "11",
day = "25",
doi = "10.2174/15680266113136660160",
language = "English (US)",
volume = "13",
pages = "2283--2290",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "18",

}

TY - JOUR

T1 - Minocycline repurposing in critical illness

T2 - Focus on stroke

AU - Liao, T. Vivian

AU - Forehand, Christy C.

AU - Hess, David C

AU - Fagan, Susan C.

PY - 2013/11/25

Y1 - 2013/11/25

N2 - Stroke is a devastating disease associated with high morbidity and mortality. Despite the approved indication of systemic thrombolytic therapy in the United States for the acute management of ischemic stroke, its use is limited given a strict eligibility criteria and a risk for hemorrhagic transformation as a feared adverse effect. Many agents have been studied without success for neuroprotection in patients with stroke to reduce vascular injury and improve long-term functional outcomes. Minocycline is a tetracycline antibiotic that shows promise for its neuroprotective effects in multiple animal models and three human trials. It affects multiple pathways to reduce apoptosis, neuroinflammation, infarct size, and vascular injury. The aim of this review is to discuss current evidence for minocycline from pre-clinical and early clinical trials and its potential role in neuroprotection in patients with acute ischemic stroke.

AB - Stroke is a devastating disease associated with high morbidity and mortality. Despite the approved indication of systemic thrombolytic therapy in the United States for the acute management of ischemic stroke, its use is limited given a strict eligibility criteria and a risk for hemorrhagic transformation as a feared adverse effect. Many agents have been studied without success for neuroprotection in patients with stroke to reduce vascular injury and improve long-term functional outcomes. Minocycline is a tetracycline antibiotic that shows promise for its neuroprotective effects in multiple animal models and three human trials. It affects multiple pathways to reduce apoptosis, neuroinflammation, infarct size, and vascular injury. The aim of this review is to discuss current evidence for minocycline from pre-clinical and early clinical trials and its potential role in neuroprotection in patients with acute ischemic stroke.

KW - Critical illness

KW - Ischemia

KW - Minocycline

KW - Neuroprotection

KW - Stroke

KW - Tetracycline

UR - http://www.scopus.com/inward/record.url?scp=84887864682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887864682&partnerID=8YFLogxK

U2 - 10.2174/15680266113136660160

DO - 10.2174/15680266113136660160

M3 - Article

C2 - 24059465

AN - SCOPUS:84887864682

VL - 13

SP - 2283

EP - 2290

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 18

ER -